Cervical Cancer Prophylaxis—State-of-the-Art and Perspectives
Open Access
- 17 July 2022
- journal article
- review article
- Published by MDPI AG in Healthcare
- Vol. 10 (7) , 1325
Abstract
Background: Each year 604,127 new cases of cervical cancer (CC) are diagnosed, and 341,831 individuals die from the disease. It is the fourth most common cancer among women and the fourth most common cause of death from female cancers worldwide. The pathogenesis of CC is associated with human papillomavirus (HPV) infections and consists of several steps involving cell proliferation outside the human body’s control mechanisms. Strategies to prevent CC are based on screening and vaccination. Scope of the Review: The aim of this paper was to collect and analyze the available literature on the issue of CC prevention and the impact of the COVID-19 pandemic on its implementation. For this purpose, PubMed and Google Scholar databases were searched using keywords, such as “cervical cancer”; “HPV”; “prevention”; “prophylaxis”; “vaccination”; “screening” and “COVID-19” in different variations. Only articles published since 2018 were included in the study. Conclusions: Selected European countries have different CC prevention programs funded by national budgets. This translates into observed differences in the risk of death from CC (age-standardized rate Malta = 1.1, Poland = 5.9). COVID-19 pandemic due to disruption of CC screening may exacerbate these differences in the future. To improve the situation, new screening methods, such as p16/Ki67, HPV self-testing, and the use of artificial intelligence in colposcopic assessment, should be disseminated, as well as free HPV vaccination programs implemented in all countries. The search for new solutions is not without significance and entails ultra-sensitive screening tests for risk groups (mRNA E6/E7, SOX1/SOX14), HPV vaccines with shorter dosing schedules, and new therapeutic pathways using nanotheranostics.Keywords
This publication has 101 references indexed in Scilit:
- Pap smear accuracy for the diagnosis of cervical precancerous lesionsTropical Doctor, 2018
- The precision prevention and therapy of HPV ‐related cervical cancer: new concepts and clinical implicationsCancer Medicine, 2018
- Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive womenVirchows Archiv, 2018
- p16/Ki67 dual staining improves the detection specificity of high‐grade cervical lesionsJournal of Obstetrics and Gynaecology Research, 2018
- Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 MonthsJAMA, 2018
- Can LBC Completely Replace Conventional Pap Smear in Developing CountriesThe Journal of Obstetrics and Gynecology of India, 2018
- Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV TypingJournal of Clinical Microbiology, 2018
- Comparative study between liquid-based cytology & conventional Pap smear for cytological follow up of treated patients of cancer cervixIndian Journal of Medical Research, 2018
- An overview of cervical cancer epidemiology and prevention in ScandinaviaActa Obstetricia et Gynecologica Scandinavica, 2018
- Comparison of conventional Pap smear and liquid-based cytology: A study of cervical cancer screening at a tertiary care center in BiharIndian Journal of Cancer, 2018